Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
WBA Stock Summary
Top 10 Correlated ETFs
WBA
In the News
Walgreens Earnings, US Eco Data, SBF Sentencing | What We're Watching
Walgreens Earnings, US Eco Data, SBF Sentencing and much more coming tomorrow.
Walgreens Earnings Are Thursday. Investors Want to See Changes.
The retail pharmacy chain reports results before the market open Thursday.
Walgreens Boots to reveal new CEO strategy in trading update
Walgreens Boots Alliance Inc (NASDAQ:WBA, ETR:W8A), the retail pharmacist, will likely showcase how its strategy is evolving under newly appointed CEO Tim Wentworth at its second quarter update on Thursday. Wentworth took charge of the group back in October 2023 but analysts are keen to learn about how he plans to deploy capital from sales over the long term and whether a ‘back to basics' plan will be launched.
Countdown to Walgreens (WBA) Q2 Earnings: A Look at Estimates Beyond Revenue and EPS
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Walgreens (WBA), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended February 2024.
Walgreens, Carnival, GameStop and More to Watch This Week
The stock market will be closed on Good Friday. Plus, core PCE price index inflation data and earnings from GameStop, Carnival, and Walgreens Boots Alliance.
Looking Ahead to Q1 Earnings
We are still a couple of weeks away from the March-quarter reporting cycle really getting underway with the big-bank results. But early results in recent days from companies for their February-ending fiscal quarters have given us some idea of what this coming earnings season will show.
Walgreens Boots Alliance (WBA) Declines More Than Market: Some Information for Investors
In the closing of the recent trading day, Walgreens Boots Alliance (WBA) stood at $20.58, denoting a -1.06% change from the preceding trading day.
Jim Cramer's week ahead: New consumer data and earnings from Walgreens
CNBC's Jim Cramer on Friday guided investors through next week's most important happenings on Wall Street.
Walgreens Boots Alliance (WBA) Stock Sinks As Market Gains: Here's Why
In the latest trading session, Walgreens Boots Alliance (WBA) closed at $20.80, marking a -1.38% move from the previous day.
Walgreens' Strategic Pivot
Walgreens Boots Alliance, Inc. faces challenges in its retail pharmacy business due to lower demand for COVID-19 testing and tight prescription drug payouts. The company is transitioning into a healthcare powerhouse, investing in primary care practices and offering in-home health services. Despite declining earnings and cash flow, there is potential for a rebound as Walgreens stock is undervalued and sales are growing in the healthcare division.
WBA Financial details
WBA Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-08-31
Metric | History | 2019-08-31 | 2020-08-31 | 2021-08-31 | 2022-08-31 | 2023-08-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 148.53 | 158.67 | 153.23 | 153.52 | 161.21 | |
Net income per share | 4.32 | 0.52 | 1.54 | 5.02 | -3.57 | |
Operating cash flow per share | 6.07 | 6.24 | 6.42 | 4.51 | 2.62 | |
Free cash flow per share | 4.22 | 4.67 | 4.83 | 2.5 | 0.16 | |
Cash per share | 1.11 | 0.59 | 2.11 | 2.86 | 0.86 | |
Book value per share | 26.21 | 24.03 | 27.55 | 33.97 | 23.21 | |
Tangible book value per share | -2.87 | -5.55 | 1.69 | -3.01 | -15.45 | |
Share holders equity per share | 26.21 | 24.03 | 27.55 | 33.97 | 23.21 | |
Interest debt per share | 19.03 | 46.37 | 39.66 | 41.51 | 39.54 | |
Market cap | 47.17B | 33.43B | 43.89B | 30.31B | 21.84B | |
Enterprise value | 62.98B | 73.06B | 76.09B | 64.42B | 54.64B | |
P/E ratio | 11.85 | 73.32 | 33.05 | 6.99 | -7.09 | |
Price to sales ratio | 0.34 | 0.24 | 0.33 | 0.23 | 0.16 | |
POCF ratio | 8.43 | 6.1 | 7.9 | 7.77 | 9.67 | |
PFCF ratio | 12.12 | 8.13 | 10.51 | 14 | 154.87 | |
P/B Ratio | 1.95 | 1.58 | 1.84 | 1.03 | 1.09 | |
PTB ratio | 1.95 | 1.58 | 1.84 | 1.03 | 1.09 | |
EV to sales | 0.46 | 0.52 | 0.57 | 0.49 | 0.39 | |
Enterprise value over EBITDA | 8.66 | 22.08 | 13.95 | 10.11 | -21.16 | |
EV to operating cash flow | 11.26 | 13.32 | 13.7 | 16.52 | 24.2 | |
EV to free cash flow | 16.18 | 17.78 | 18.22 | 29.76 | 387.53 | |
Earnings yield | 0.08 | 0.01 | 0.03 | 0.14 | -0.14 | |
Free cash flow yield | 0.08 | 0.12 | 0.1 | 0.07 | 0.01 | |
Debt to equity | 0.7 | 1.9 | 1.4 | 1.21 | 1.67 | |
Debt to assets | 0.25 | 0.46 | 0.41 | 0.39 | 0.35 | |
Net debt to EBITDA | 2.18 | 11.97 | 5.9 | 5.35 | -12.71 | |
Current ratio | 0.73 | 0.67 | 0.72 | 0.75 | 0.63 | |
Interest coverage | 7.1 | 2.05 | 3.85 | 10.96 | -11.87 | |
Income quality | 1.41 | 12.93 | 2.21 | 0.96 | -0.64 | |
Dividend Yield | 0.03 | 0.05 | 0.04 | 0.05 | 0.08 | |
Payout ratio | 0.41 | 3.83 | 1.22 | 0.38 | -0.54 | |
Sales general and administrative to revenue | 0.18 | 0.19 | 0.18 | 0.2 | 0.24 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0.24 | 0.3 | 0.28 | 0.37 | 0.43 | |
Capex to operating cash flow | -0.3 | -0.25 | -0.25 | -0.44 | -0.94 | |
Capex to revenue | -0.01 | -0.01 | -0.01 | -0.01 | -0.02 | |
Capex to depreciation | -0.84 | -0.71 | -0.7 | -0.87 | -0.94 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 50.48 | 16.75 | 30.85 | 61.93 | 43.17 | |
ROIC | 0.1 | 0.01 | 0.03 | 0.05 | -0.06 | |
Return on tangible assets | 0.08 | 0.01 | 0.02 | 0.08 | -0.06 | |
Graham Net | -35.09 | -63.05 | -54.71 | -57.04 | -68.66 | |
Working capital | -7.07B | -9B | -6.24B | -5.68B | -9.03B | |
Tangible asset value | 8.23B | -4.89B | 1.47B | -2.6B | -13.33B | |
Net current asset value | -24.75B | -47.97B | -41.65B | -42.81B | -52.64B | |
Invested capital | 0.7 | 1.9 | 1.4 | 1.21 | 1.67 | |
Average receivables | 6.9B | 7.18B | 6.4B | 5.34B | 5.2B | |
Average payables | 13.95B | 14.4B | 12.8B | 11.2B | 11.95B | |
Average inventory | 9.45B | 9.39B | 8.81B | 8.26B | 8.31B | |
Days sales outstanding | 19.27 | 18.66 | 15.6 | 13.8 | 14.12 | |
Days payables outstanding | 49.02 | 47.32 | 38.92 | 39.34 | 41.17 | |
Days of inventory on hand | 31.9 | 30.93 | 28.51 | 29.19 | 26.91 | |
Receivables turnover | 18.94 | 19.56 | 23.4 | 26.45 | 25.85 | |
Payables turnover | 7.45 | 7.71 | 9.38 | 9.28 | 8.86 | |
Inventory turnover | 11.44 | 11.8 | 12.8 | 12.5 | 13.57 | |
ROE | 0.16 | 0.02 | 0.06 | 0.15 | -0.15 | |
Capex per share | -1.85 | -1.56 | -1.59 | -2.01 | -2.45 |
Quarterly Fundamentals Overview
Last date of statement is 2023-11-30 for Q1
Metric | History | 2022-11-30 | 2023-02-28 | 2023-05-31 | 2023-08-31 | 2023-11-30 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 38.67 | 40.42 | 41.03 | 41.35 | 42.53 | |
Net income per share | -4.43 | 0.62 | -0.06 | -0.21 | -0.08 | |
Operating cash flow per share | 0.57 | 0.86 | -0.02 | 1.21 | -0.33 | |
Free cash flow per share | -0.14 | 0.29 | -0.63 | 0.65 | -0.91 | |
Cash per share | 4.9 | 2.13 | 1.12 | 0.86 | 0.91 | |
Book value per share | 28.47 | 34.13 | 34.02 | 23.37 | 31.97 | |
Tangible book value per share | -9.79 | -14.62 | -14.4 | -15.56 | -15.88 | |
Share holders equity per share | 28.47 | 34.13 | 34.02 | 23.37 | 31.97 | |
Interest debt per share | 41.26 | 43.73 | 42.42 | 39.33 | 39.21 | |
Market cap | 35.83B | 30.65B | 26.21B | 21.68B | 17.21B | |
Enterprise value | 68.99B | 67.14B | 61.78B | 54.49B | 50.16B | |
P/E ratio | -2.34 | 14.27 | -126.02 | -30.11 | -64.21 | |
Price to sales ratio | 1.07 | 0.88 | 0.74 | 0.61 | 0.47 | |
POCF ratio | 72.67 | 41.08 | -1.31K | 20.87 | -61.24 | |
PFCF ratio | -306.23 | 123.58 | -48.1 | 39.07 | -21.87 | |
P/B Ratio | 1.46 | 1.04 | 0.89 | 1.08 | 0.62 | |
PTB ratio | 1.46 | 1.04 | 0.89 | 1.08 | 0.62 | |
EV to sales | 2.07 | 1.93 | 1.74 | 1.54 | 1.37 | |
Enterprise value over EBITDA | -14.79 | 51.33 | 159.23 | 141.53 | 140.51 | |
EV to operating cash flow | 139.94 | 90 | -3.09K | 52.44 | -178.51 | |
EV to free cash flow | -589.67 | 270.71 | -113.36 | 98.18 | -63.74 | |
Earnings yield | -0.11 | 0.02 | 0 | -0.01 | 0 | |
Free cash flow yield | 0 | 0.01 | -0.02 | 0.03 | -0.05 | |
Debt to equity | 1.44 | 1.28 | 1.24 | 1.67 | 1.22 | |
Debt to assets | 0.38 | 0.37 | 0.37 | 0.35 | 0.34 | |
Net debt to EBITDA | -7.11 | 27.9 | 91.67 | 85.21 | 92.31 | |
Current ratio | 0.7 | 0.63 | 0.63 | 0.63 | 0.66 | |
Interest coverage | -56.41 | 5.3 | -1.21 | -2.91 | -0.39 | |
Income quality | -0.13 | 1.37 | 0.42 | -5 | 1.01 | |
Dividend Yield | 0.01 | 0.01 | 0.02 | 0.02 | 0.02 | |
Payout ratio | -0.11 | 0.77 | -7.98 | -2.31 | -6.19 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0.18 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0.01 | 0 | |
Intangibles to total assets | 0.36 | 0.42 | 0.43 | 0.43 | 0.42 | |
Capex to operating cash flow | -1.24 | -0.67 | 26.25 | -0.47 | 1.8 | |
Capex to revenue | -0.02 | -0.01 | -0.01 | -0.01 | -0.01 | |
Capex to depreciation | -1.23 | -0.89 | -0.88 | -0.8 | -0.82 | |
Stock based compensation to revenue | 0.01 | 0 | 0 | 0 | 0 | |
Graham number | 53.26 | 21.86 | 6.79 | 10.51 | 7.47 | |
ROIC | -0.05 | 0.01 | 0 | 0 | 0 | |
Return on tangible assets | -0.06 | 0.01 | 0 | 0 | 0 | |
Graham Net | -64.4 | -69.98 | -69.11 | -69.15 | -69.61 | |
Working capital | -8.51B | -10.54B | -9.63B | -9.03B | -8.77B | |
Tangible asset value | -8.46B | -12.61B | -12.43B | -13.33B | -13.71B | |
Net current asset value | -48.61B | -53.19B | -52.54B | -52.64B | -52.72B | |
Invested capital | 1.44 | 1.28 | 1.24 | 1.67 | 1.22 | |
Average receivables | 4.94B | 5.29B | 5.79B | 5.61B | 5.68B | |
Average payables | 11.72B | 12.45B | 12.37B | 12.33B | 13.11B | |
Average inventory | 8.84B | 9.04B | 8.46B | 8.21B | 8.86B | |
Days sales outstanding | 13.08 | 14.79 | 14.85 | 13.67 | 14.64 | |
Days payables outstanding | 41.49 | 41.17 | 37.56 | 39.28 | 40.86 | |
Days of inventory on hand | 31.74 | 28.34 | 25.49 | 25.67 | 28.42 | |
Receivables turnover | 6.88 | 6.08 | 6.06 | 6.58 | 6.15 | |
Payables turnover | 2.17 | 2.19 | 2.4 | 2.29 | 2.2 | |
Inventory turnover | 2.84 | 3.18 | 3.53 | 3.51 | 3.17 | |
ROE | -0.16 | 0.02 | 0 | -0.01 | 0 | |
Capex per share | -0.71 | -0.58 | -0.61 | -0.56 | -0.59 |
WBA Frequently Asked Questions
What is Walgreens Boots Alliance, Inc. stock symbol ?
Walgreens Boots Alliance, Inc. is a US stock , located in Deerfield of Il and trading under the symbol WBA
Is Walgreens Boots Alliance, Inc. buy or a sell ?
30 stock analysts have 30 predictions with a medium analyst target price of $41.53. The lowest prediction is $2 and the highest is $57
What is WBA stock prediction ?
With a median analyst target price of $20.5, 4 stock analysts have made 4 forecasts in last 90 days. $2 is the lowest and $37 is the greatest projection.
What is Walgreens Boots Alliance, Inc. stock quote today ?
Walgreens Boots Alliance, Inc. stock price is $21.785 today.
Is Walgreens Boots Alliance, Inc. stock public?
Yes, Walgreens Boots Alliance, Inc. is a publicly traded company.